Evaluation Program Is Open to Qualified Hospitals and Surgical Centers
WOLF CREEK, MT / ACCESSWIRE / April 19, 2021 / Solo-Dex, a developer and distributor of medical catheters, announces the national availability of its Facile® continuous peripheral nerve block (cPNB catheter for managing pain before, during and after surgery. All Solo-Dex products are currently US FDA cleared and CE marked for Europe.
With Facile®, anesthesiologists can place and activate the facile continuous nerve block catheter quickly and safely for common procedures such as shoulder repair, hip and knee replacement as well as general surgical procedures. Facile leads the field in ease-of-use placement. The SOLO-DEX Fascile® simplifies and accelerates cPNB placement, improving patient comfort and post-procedure pain management. Patients report the need for opioids is drastically reduced and often eliminated altogether.
Regional anesthesia coupled with mild sedation may eliminate the need for a patient to receive general anesthesia which requires the manipulation of the airway. Manipulation of the airway increases the risk of Covid-19 exposure for the surgical team.
"Before the introduction of Solo-Dex Facile, the use of continuous regional anesthesia has been limited to a small group. Fascile has been developed specifically for the ease-of-use market which is up to 10 times larger than the current nerve catheter market," says Steve Eror, CEO of Solo-Dex.
Regional anesthesia established and maintained by a small catheter offers safe and effective pain management for days before, during and after surgery. The patient tends to recover more quickly and may be released for home recovery with a block that eliminates the need for oral opioid painkillers.
According to the CDC, 40 people die from overdoses involving prescription opioids. The real cost of Opioid abuse is $1 Trillion from 2001-2017 according to the NY Times.
Interested physicians can obtain more information at www.solo-dex.com
Solo-Dex is a developer and distributor of medical catheter, founded by leading anesthesiologists to reduce the cost and risk associated with general anesthesia by improving surgical patient recovery times, reducing medical personnel exposure to covid-19, reducing or eliminating the misuse of opioid-related pain management, and by safely and effectively managing pain before, during and after a procedure. For more information about SOLO-DEX, please log on to www.solo-dex.com
Janet Vasquez, Public Relations
SOURCE: Solo-Dex, Inc.
View source version on accesswire.com: